Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 07:25PM GMT
Release Date Price: R$24.45 (-2.36%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm biotech analyst at Barclays. Welcome to our second virtual global healthcare conference. First, I wish everyone stay healthy. And I would like to thank all the participants: investors, companies, and also, particularly our event team and the corporate access team, who made this virtual health care conference possible.

With that, I would like to introduce our next presenting company, Sarepta. With us today, we have Doug Ingram, President and Chief Executive Officer. We have Gilmore O'Neill, our Chief Medical Officer. And also, we have Ian Estepan, Chief Financial Officer.

With that, I hand over to you, Doug, to give a brief overview of the company, and then we jump into Q&A.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

And I'll be very brief. Gena, first, thank you for having us today. We're excited to talk about our various programs. As you know, for those who may be less familiar with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot